BiDil Side Effects
BiDil (hydralazine and isosorbide dinitrate) causes headache in approximately 50% of patients, along with frequent dizziness (30%), and less commonly nausea, hypotension, and ventricular tachycardia, with adverse events being poorly tolerated and contributing to low prescription refill rates in clinical practice. 1
Most Common Side Effects
The A-HeFT trial, which established BiDil's efficacy in heart failure, documented the following adverse event rates compared to placebo 1:
- Headache: 50% vs 21% (most common)
- Dizziness: 30% vs 14%
- Asthenia (weakness): 14% vs 11%
- Nausea: 10% vs 6%
- Hypotension: 8% vs 4%
- Sinusitis: 4% vs 2%
- Ventricular tachycardia: 4% vs 2%
- Paresthesia: 4% vs 2%
- Vomiting: 4% vs 2%
Clinical Tolerability Issues
The 2022 AHA/ACC/HFSA guidelines explicitly note that uptake of BiDil has been modest due to "the complexity of the medical regimen and the array of drug-related adverse effects," with marked underusage based on very low prescription refill rates even when prescribed. 2 This poor tolerability is a major barrier to achieving the target doses (hydralazine 75 mg/isosorbide dinitrate 40 mg three times daily) that were used in the clinical trials demonstrating benefit.
Additional Adverse Effects from Post-Marketing Experience
Beyond the trial data, the FDA label documents additional side effects reported in clinical use 1:
Cardiovascular: Facial flushing, chest discomfort, chest pain, peripheral edema, syncope
Gastrointestinal: Abdominal discomfort, constipation, diarrhea, altered taste
Neurological: Migraine, reduced sensation, facial pain
Genitourinary: Erectile dysfunction, urine discoloration
Dermatologic: Excessive sweating, itching, redness, facial swelling
Respiratory: Shortness of breath
Ocular: Eyelid edema, blurred vision, tearing, conjunctivitis
Serious but Rare Adverse Effects
The FDA label warns of potentially serious complications 1:
- Blood disorders: Agranulocytosis, purpura, eosinophilia, splenomegaly
- Hepatitis
- Psychotic reactions and disorientation
- Pulmonary-renal syndrome
- Paralytic ileus
Overdose Manifestations
Signs of BiDil overdose reflect excessive vasodilation 1:
- Severe headache
- Confusion and syncope
- Tachycardia
- Generalized skin flushing
- Profound hypotension and shock
- Potential myocardial ischemia/infarction
- Cardiac arrhythmias
- Methemoglobinemia (particularly concerning in heart failure patients with already compromised oxygen delivery)
Important Clinical Caveats
A 2017 study in heart failure with preserved ejection fraction found that 61.5% of patients on isosorbide dinitrate alone and 60% on the combination experienced adverse events, compared to only 12.5% on placebo (P=0.007), demonstrating the substantial side effect burden. 3 This study also showed that adding hydralazine to isosorbide dinitrate may actually worsen some outcomes, including exercise capacity.
In dialysis patients, a 2020 pilot trial found that while the combination was generally tolerated, nausea was significantly more frequent (1.90 vs 0.50 events/patient-year, P=0.03), and headache and diarrhea were numerically more common with BiDil. 4
Monitoring Recommendations
Based on the FDA label, monitor 1:
- Blood pressure (especially during dose titration)
- Electrolytes
- Renal function
- Signs of methemoglobinemia in overdose situations
The side effect profile of BiDil represents a significant barrier to optimal dosing and adherence, which partially explains why clinical outcomes in real-world practice may not match the impressive trial results, particularly when patients cannot tolerate the high doses required for maximal benefit.